Bristol Myers Squibb Presents New Data From 2-Trials Demonstrating Sotyktu Efficacy In both Moderate-To-Severe Scalp Psoriasis And In A Real-World Setting; In The Phase 3b/4 PSORIATYK SCALP Sotyktu Was Superior To Placebo Across All Primary And Secondary Endpoints At Week 16, With Patients Reporting Significantly Greater Improvement In Symptoms
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb announced positive results from the Phase 3b/4 PSORIATYK SCALP trial, demonstrating the efficacy of Sotyktu in treating moderate-to-severe scalp psoriasis. The trial showed Sotyktu's superiority over placebo in all primary and secondary endpoints at Week 16, with significant symptom improvement. The safety profile was consistent with previous studies.
September 27, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Sotyktu demonstrated significant efficacy in treating moderate-to-severe scalp psoriasis in recent trials, outperforming placebo. This positive data could enhance Sotyktu's market potential and support BMY's stock performance.
The positive trial results for Sotyktu in treating scalp psoriasis suggest enhanced efficacy and safety, which could lead to increased adoption and sales. This is likely to positively impact Bristol Myers Squibb's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100